Head & Neck Cancers

Sharon Spencer, MD, professor, chief of Medical Services, Ruby Meredith Outstanding Clinician Endowed Chair, University of Alabama at Birmingham School of Medicine, discusses the types of radiation therapy available to patients with head and neck cancer.

The FDA has granted a priority review designation to pembrolizumab (Keytruda) as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Jonathan D. Schoenfeld, MD, discusses potential synergy between radiation therapy, given with or without chemotherapy, and immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.

Next-generation sequencing efforts focusing on the most common form, head and neck squamous cell carcinoma, are illuminating the hidden complexities of its genome.

Jessica Frakes, MD, explains findings from a study that examined treatment and follow-up for HPV-associated oropharynx cancer, and how they could impact clinical practice for the follow-up of patients with the disease.

Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.

Ezra Cohen, MD, discusses results of a biomarker analysis and the next steps in understanding biomarkers for afatinib in patients with head and neck cancer.

An expert panel has developed clinical practice guidelines for the management of head and neck cancer survivors.

David Sher, MD, radiation oncologist, UT Southwestern Medical Center, provides an update on and the basis for ASTRO's Multidisciplinary Head and Neck Cancer Guideline.